The purpose of the Thoracic Society of Australia and New Zealand guidelines is to provide simple, practical evidence-based recommendations for the acute use of oxygen in adults in clinical practice.The intended users are all health professionals responsible for the administration and/or monitoring of oxygen therapy in the management of acute medical patients in the community and hospital settings (excluding perioperative and intensive care patients), those responsible for the training of such health professionals, and both public and private health care organizations that deliver oxygen therapy.
INTRODUCTION

Systematic review
The 2008 and draft 2015 British Thoracic Society (BTS) Guidelines for Emergency Oxygen Use in Adult Patients 1,2 were reviewed, including all references in these documents, which were evaluated in their entirety, together with additional references and texts where relevant. A systematic review was not performed for the purpose of developing this guideline. The BTS commissioned the Centre for Reviews and Dissemination and Centre for Health Economics at the University of York, UK, to undertake bespoke literature searches, using defined search strategies (appendix 14 in http://www.brit-thoracic.org.uk). While the Thoracic Society of Australia and New Zealand (TSANZ) Oxygen Guideline recommendations are similar to the BTS 2015 Oxygen Guidelines, there are a number of key differences including the general target oxygen saturation range (92-96% vs 94-98%) and the algorithms for emergency use of oxygen including greater emphasis on titration of oxygen administered via nasal cannulae. In contrast to the BTS 2015 Oxygen Guidelines, an extensive list of references is not provided, but rather reference is made to key reviews, studies and guidelines where appropriate. Readers are referred to the 2015 BTS guidelines for the more comprehensive detail that it provides.
Grading
Grades of recommendation (Table 1) relate to the Australian National Health and Medical Research Council grading system based on level of evidence, consistency of that evidence, clinical impact, generalizability and applicability. 3 For a full explanation of the recommendation grades, please go to https://www.nhmrc.gov.au/_files_nhmrc/ file/guidelines/developers/nhmrc_levels_grades _evidence_120423.pdf
Guideline Development Group
This group included representatives from a range of professions and disciplines relevant to the scope of the guidelines.
Peer review
The draft guidelines were peer-reviewed by the Australasian College for Emergency Medicine, the Australian and New Zealand College of Anaesthetists, the Australian College of Nursing Ltd, the Cardiac Society of Australia and New Zealand, the Australian and New Zealand Intensive Care Society, the Australian Physiotherapy Association, the Council of Ambulance Authorities Inc. and the Internal Medicine Society of Australia and New Zealand.
Presentation
The guidelines are presented in the format of key concepts, the recommendations with grades of evidence and practice points, and the background evidence on which the recommendations are based. Key recommendations are summarized in Table 2 .
Dissemination plan
The guidelines will be sent to medical and nursing directors of hospitals, primary care organizations and ambulance services, and the deans of medical, physiotherapy and nursing schools in Australia and New Zealand.
Implementation
The implementation of these guidelines by organizations will require communication, education and training strategies, and an audit system for monitoring compliance within a designated timeframe.
Expiry date
2019.
CONCEPTS
1 Oxygen should be considered as a drug that is prescribed and administered for specific indications, with a documented target oxygen saturation range and with regular monitoring of the patient's response. 2 Oxygen is prescribed for the relief of hypoxaemia, not breathlessness. 3 Hypoxaemia is both a marker of risk of a poor outcome due to the severity of the underlying disease(s) that has caused hypoxaemia, and an independent risk factor of poor outcome. 4 There are risks associated with both hypoxaemia and hyperoxaemia, which underlie the importance of prescribing oxygen only if required, and to within a target oxygen saturation range. 5 The 'swimming between the flags' concept of titrating oxygen therapy, to within a specific target oxygen saturation range applies to a wide range of clinical situations, in addition to exacerbations of chronic obstructive pulmonary disease (COPD). 6 The variable accuracy of pulse oximetry in the estimation of arterial oxygen saturation (SaO2) represents the major limitation in its use to guide the titration of oxygen therapy. 7 The use of high concentration oxygen in a breathless patient in an attempt to protect against hypoxaemia in the event of a subsequent deterioration has the potential to cause delay in recognizing clinical deterioration and reduce the time available to initiate additional treatment. 8 If a patient who requires a high fraction of inspired oxygen (FiO2) to maintain adequate oxygen saturations deteriorates, there is limited opportunity to increase FiO2 to avoid life-threatening hypoxaemia. For this reason, patients who need high FiO2 should receive senior clinician review and transfer to an area where there are appropriate numbers of competent staff able to provide more intensive monitoring and therapy.
RECOMMENDATIONS Assessment
1 Pulse oximetry should be available in all clinical situations in which oxygen is used. 4 [Grade C] Practice point: There is variable accuracy of pulse oximetry to predict SaO2 in acutely ill patients, with SaO2 measurements by pulse oximeter (SpO2) both over and underestimating SaO2, with wide limits of agreement. [4] [5] [6] [7] [8] [9] The accuracy of SpO2 may worsen with increasingly severe hypoxaemia. 8, 9 Clinicians need to ABG, arterial blood gas; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen; HDU, high dependency unit; ICU, intensive care unit; NIV, non-invasive ventilation; PaCO2, arterial partial pressure of carbon dioxide; SpO2, arterial oxygen saturation measured by pulse oximeter.
be aware of the variable accuracy of SpO2 in the utilization of pulse oximetry in clinical practice. An SpO2 of ≥92% is a practical lower threshold to rule out hypoxaemia, defined as an SaO2 of <90% 7 or an arterial partial pressure of oxygen (PaO2) of <60 mm Hg (8 kPa). 5 2 Arterial blood gas (ABG) measurement should be considered in the following situations. [Grade C]
• Critically ill patients with cardiorespiratory or metabolic dysfunction • In patients with an SpO2 of <92% in whom hypoxaemia may be present • Deteriorating SpO2 requiring increased FiO2
• Patients at risk of hypercapnia • Breathless patients in whom a reliable oximetry signal cannot be obtained.
Peripheral venous blood gas analysis is a less invasive test; however, it does not provide an accurate estimate of arterial partial pressure of carbon dioxide (PaCO2) or PaO2. 10 It does, however, provide rapid clinically important information to assess acutely unwell patients, including pH, lactate, glucose, haemoglobin, sodium and potassium. In addition it provides a venous PCO2 which if less than 40 mm Hg, effectively rules out hypercapnia. 10 Arterialized capillary earlobe or fingertip blood gas measurements represent an alternative if unable to obtain an ABG measurement, recognizing that while providing accurate information about PaCO2 and pH, they variably underestimate PaO2 measurements. 11, 12 As a result, patient assessment can be based on pH and partial pressure of carbon dioxide (PCO2) levels measured from earlobe or fingertip blood gases, together with SpO2 by pulse oximetry.
Practice point: Hypoxaemia requires investigation and treatment of the underlying cause, and consideration of the contribution of hypoventilation, including measurement of PaCO2 and pH.
Prescription
1 A specific oxygen prescription should be documented in the patient records and the drug chart.
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[Grade D]
Practice point: The main requirement for an oxygen prescription is documentation of the target SpO2 range.
In its most detailed form, the prescription could include the delivery system and interface, the target oxygen saturation range, the range of flow rates for each delivery system, and instruction as to SpO2 and FiO2 at which clinical review should be sought. Considerable space on the prescription form is needed to provide such detail.
Oxygen administration (see Fig. 1) 1 An SpO2 target of 88-92% is recommended in exacerbations of COPD 14 [Grade B] and other conditions associated with chronic respiratory failure (such as obesity hypoventilation syndrome, 15 bronchiectasis, cystic fibrosis, 16 neuromuscular disease and chest wall deformities such as severe kyphoscoliosis).
[Grade C]
Practice points: Where there is diagnostic uncertainty as to whether COPD is the primary cause of the exacerbation, it may be preferable to titrate oxygen therapy to the 88-92% SpO2 target range. 14, [17] [18] [19] If the patient is breathing room air and has a saturation of ≥88%, then the initiation of oxygen is not routinely required and may result in oxygen saturations outside the target saturation range. 2 In the presence of hypoxaemia in other acute medical conditions, oxygen should be administered to achieve a target SpO2 range of 92-96%. 20, 21 [Grade C] Practice point: If the patient is breathing room air and has a saturation of ≥92%, then the initiation of oxygen is not routinely required and may place the patient at risk of oxygen saturations outside the target saturation range. 3 A target of around 85% is recommended in patients previously exposed to bleomycin or in paraquat poisoning. [22] [23] [24] [Grade C] 4 Patients with carbon monoxide poisoning should receive normobaric hyperoxia or hyperbaric oxygen therapy. 25, 26 [Grade B] Note that pulse oximetry is likely to be inaccurate in this setting. 4 Practice point: In the immediate assessment of an acutely unwell patient, oxygen saturations should be measured by oximetry, pending the availability of blood gas results if required (See Assessment, Point 2). a. In the presence of COPD or conditions associated with chronic respiratory failure:
• If SpO2 ≥ 88%, oxygen therapy is not initially required.
• If SpO2 < 88%, oxygen can be administered at 1-2 L/min via nasal cannulae or 2-4 L/min via 24% or 28% Venturi mask, and titrated to achieve target SpO2.
• The avoidance of inappropriate high concentration oxygen therapy may be facilitated by the provision of a COPD oxygen alert card. 27 b. In the absence of COPD or known chronic respiratory failure:
• If SpO2 ≥ 92%, oxygen therapy is not routinely required.
• If SpO2 is 85-91%, oxygen can be initially instituted at 2-4 L/min via nasal cannulae or other suitable oxygen delivery method, and titrated to achieve target SpO2. In many situations, this range of oxygen saturations is unlikely to be associated with risk, although oxygen is commonly administered.
• If SpO2 < 85%, oxygen can be initiated at 4 L/min via nasal cannulae, through a simple face mask at 5-10 L/min, a 100% non-rebreather reservoir mask at 15 L/min, or humidified high flow nasal cannulae (FiO2 > 0.35). The choice of delivery system will depend on the SpO2 level (higher FiO2 will be required with greater reductions in SpO2), and titrated to achieve the target SpO2 as soon as practically possible.
Practice point: If oximetry is not available, or reliable SpO2 cannot be determined and hypoxaemia is suspected, oxygen can be delivered at: • 1-2 L/min via nasal cannulae or 2-4 L/min via 24% or 28% Venturi mask in patients with acute exacerba-tions of COPD or conditions known to be associated with chronic respiratory failure.
• 2-4 L/min oxygen via nasal cannulae in patients who are not critically ill and life-threatening hypoxaemia is not suspected.
• 5-10 L/min via simple face mask, 15 L/min through a 100% non-rebreather reservoir mask or high flow nasal cannulae (FiO2 > 0.35) in patients in whom life-threatening hypoxaemia is suspected (see Fig. 1 ).
Monitoring
1 Monitoring of SpO2 is a fundamental requirement for a target SpO2 to be achieved. 2 An important component of monitoring is documentation of the delivery system and flow rate, in addition to documentation of the SpO2. Figure 1 Treatment algorithm for oxygen therapy. Please refer to the text for full recommendations, references and evidence grading. *Such as COPD, obesity hypoventilation syndrome, chest wall deformities, cystic fibrosis, bronchiectasis or neuromuscular disease. †If oximetry is not available, or reliable oxygen saturations cannot be determined and hypoxaemia is suspected, oxygen can be delivered at: ○ 1-2 L/min via nasal cannulae or 2-4 L/min via 24% or 28% Venturi mask in patients with acute exacerbations of COPD or conditions known to be associated with chronic respiratory failure.* ○ 2-4 L/min oxygen via nasal cannulae in patients who are not critically ill and life-threatening hypoxaemia is not suspected. ○ 5-10 L/min via simple face mask, or 15 L/min through a 100% non-rebreather reservoir mask, or high flow nasal cannulae (FiO2 > 0.35) in patients who are critically ill or in whom life-threatening hypoxaemia is suspected (e.g. post-cardiac arrest or resuscitation, shock, sepsis, near drowning, anaphylaxis, major head injury or in suspected carbon monoxide poisoning). NIV or invasive ventilation and transfer to HDU or ICU should also be considered in this situation. ABG, arterial blood gas; COPD, chronic obstructive pulmonary disease; HDU, high dependency unit; HFNC, high flow nasal cannulae; ICU, intensive care unit; MDI, metered dose inhaler; NIV, non-invasive ventilation; O2, oxygen; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; Sats, oxygen saturations; SpO2, oxygen saturation determined by pulse oximetry. 
Bronchodilator administration
1 In COPD and other conditions associated with chronic respiratory failure, if a bronchodilator is required, the preferred methods of administration are via an air-driven nebulizer or via a metered dose inhaler +/− a spacer, with supplementary nasal oxygen continued as required.
14,42 [Grade B] Practice point: The administration of bronchodilator via an oxygen-driven nebulizer has the potential to cause an increase in PaCO2. 43, 44 It has been recommended that if an oxygen-driven nebulizer is used in a patient with an exacerbation of COPD, then its use is limited to 6 min. 
46-48
Ventilatory support
1 In patients with hypercapnic respiratory failure, in whom an ABG measurement shows a pH of <7.35 and PaCO2 of >45 mm Hg, non-invasive ventilation (NIV) or invasive ventilation should be considered. [49] [50] [51] [52] [53] [Grade A] COPD patients with a pH of <7.26 managed with NIV require more intensive monitoring with a low threshold for intubation. 52 2 In patients in whom oxygen-induced hypercapnia is suspected, oxygen therapy should be titrated to maintain the 88-92% target oxygen saturation range and not be abruptly stopped due to the risk of profound rebound hypoxaemia. 54 
BACKGROUND EVIDENCE
1 Oxygen therapy does not relieve breathlessness in the absence of hypoxaemia. For example, there is no clinical benefit with short burst oxygen therapy in COPD patients with breathlessness, 64 or with the use of oxygen over room air via nasal cannulae for patients with COPD who do not have severe resting hypoxaemia. 65 Similarly, there is no additional symptomatic benefit in the use of oxygen over room air via nasal cannulae for refractory breathlessness in the palliative setting. 66 In the absence of hypoxaemia, oxygen therapy is not indicated in the treatment of acute coronary syndrome or stroke, conditions associated with reversible ischaemia. In myocardial infarction, high concentration oxygen therapy is associated with greater infarct size, when compared with room air or titrated oxygen therapy if required to avoid hypoxaemia. 67, 68 In stroke, routine administration of continuous or nocturnal oxygen therapy does not improve outcomes.
69,70
2 Hypoxaemia is both a marker of risk of a poor outcome due to the severity of the underlying disease(s) that has caused hypoxaemia, and an independent risk factor of poor outcome. 28, 71 The clinical impact depends on the underlying cause(s), the speed of onset and severity of hypoxaemia, the age of the patient and associated co-morbidities. It has been proposed that an PaO2 of 50 mm Hg (6.6 kPa) can be considered as the safe lower limit of hypoxaemia in patients with COPD, 72 and that oxygen therapy that achieves an PaO2 of at least 50 mm Hg would prevent immediate death from hypoxaemia. 73 3 The potential risks due to hyperoxaemia with high concentration oxygen therapy include respiratory (increased PaCO2, absorption atelectasis and direct pulmonary toxicity), cardiovascular (increased systemic vascular resistance and blood pressure, reduced coronary artery blood flow, reduced cardiac output), cerebrovascular (reduced cerebral blood flow) effects and increased reperfusion injury due to increased reactive oxygen species. [74] [75] [76] [77] [78] 4 The physiological response of an increase in PaCO2 due to high concentration oxygen therapy has been demonstrated not only in stable and acute exacerbations of COPD, 72 but also in severe asthma, 20, 79 community-acquired pneumonia 21 and obesity hypoventilation syndrome. 15 Proposed mechanisms for oxygen-induced hypercapnia include increased ventilation perfusion mismatch due to reduced hypoxic pulmonary vasoconstriction, reduced ventilatory drive, atelectasis and the Haldane effect, with the contribution of each likely to depend on the clinical situation. 5 There is variable accuracy of pulse oximetry to predict SaO2 in acutely ill patients, with SpO2 measurements both over and under estimating SaO2, with wide limits of agreement. [4] [5] [6] [7] [8] [9] Clinicians need to be aware of the variable accuracy of SpO2 in the utilization of pulse oximetry in clinical practice. Factors that might affect the accuracy of pulse oximetry include severe hypoxaemia, carboxyhaemoglobin and methaemoglobin levels, anaemia, dark skin, low perfusion, excessive ambient light and nail polish. 4, 8, 9 6 The use of high flow oxygen in an attempt to protect against subsequent hypoxaemia in the event of deterioration has the potential to delay the recognition of such a deterioration. 80, 81 This may provide a false reassurance that the patient is stable. There is likely to be no major change in vital signs 82 or a marked decrease in SpO2 as assessed by pulse oximetry 83 until a potentially life-threatening situation has developed. At this stage there is limited opportunity to further increase the oxygen therapy while medical review and an intervention such as transfer to an HDU or ICU is undertaken. Similarly, if a patient who requires a high FiO2 to maintain adequate SpO2 deteriorates there is limited capacity to increase FiO2 to avoid life-threatening hypoxaemia. For this reason it is recommended that patients who need an FiO2 of ≥0.40, such as ≥6 Litres per minute via a simple face mask, to maintain an adequate SpO2, should receive senior clinician review and may require transfer to a ward area, such as an HDU. Likewise, patients who need an FiO2 ≥0.50, such as ≥8 L/min via a simple face mask, to maintain an adequate SpO2, should receive ICU review as most will require ICU transfer. 7 Peripheral venous blood gas analysis is a less invasive test than an ABG; however, it does not provide an accurate estimate of PaCO2 or PaO2. It does, however, provide rapid clinically important information to assess acutely unwell patients, including pH, lactate, glucose, haemoglobin, sodium and potassium. In addition it provides a PCO2 that, if less than 40 mm Hg, essentially rules out hypercapnia. A systematic review and meta-analysis has compared venous and ABG measurements. 10 The point estimate for the difference between PaCO2 and venous PCO2 was 4.1 mm Hg higher for the venous reading, but with wide 95% confidence limits from 10.7 mm Hg higher to 2.4 mm Hg lower. PaO2 was higher than venous PO2 by 36.9 mm Hg with a 95% confidence interval of 27.2-46.6 mm Hg. Arterial pH values were slightly higher than venous pH; 0.03 with a 95% confidence interval of 0.029-0.038. 8 A target SpO2 range of 88-92% is recommended in the treatment of COPD and other conditions associated with chronic respiratory failure due to demonstration of:
• A greater than twofold reduction in mortality with pre-hospital oxygen therapy titrated to this target, compared with high concentration oxygen therapy in patients with an acute exacerbation of COPD.
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• An increase in PaCO2 with 100% oxygen therapy in patients with chronic respiratory failure due to obesity hypoventilation syndrome. 15 9 A general target SpO2 range of 92-96% in acute medical conditions has been recommended, incorporating a lower range than that recommended in the BTS guidelines (94-98%). This lower target recognises that:
• An SpO2 of ≥92% is a practical lower threshold to rule out hypoxaemia, defined as an SaO2 of <90% 7 or an PaO2 of <60 mm Hg (8 kPa).
5
• There is no known risk of hypoxic tissue injury at an SaO2 of 90%.
• Older healthy subjects have SaO2 levels to this lower level of 90%. 84, 85 • Healthy subjects have a mean nadir SpO2 of around 90% during sleep.
86
• Subjects with sleep-disordered breathing commonly tolerate SpO2 levels between 80% and 90% for prolonged periods.
• Adults with co-morbidities tolerate SpO2 levels between 80% and 90% during long distance travel.
87
• Guidelines for acute coronary syndrome 88 and heart failure 89 recommend administration of oxygen if the SpO2 is <93% and <90%, respectively.
• In adults with coronary artery disease, anaerobic metabolism indicative of myocardial ischaemia is observed in some patients with SaO2 between 70% and 85%, suggesting a 'safe' lower limit of oxygen saturation of 90%. 90 • There is an evidence base for titration of oxygen therapy to a target SpO2 range of 93-95% in acute severe asthma, 20 and community-acquired pneumonia. 21 • There is an evidence base for the safety of oxygen therapy to a target SpO2 range of 88-92% in acute exacerbations of COPD. 14 • This recommendation is likely to reduce excessive use of high concentration oxygen therapy.
• An upper level of 96% avoids the potential risks of hyperoxia and allows for patient improvement to be recognized earlier during monitoring, so that oxygen can be down-titrated. 10 A target SpO2 range of 85% is recommended in patients with prior exposure to bleomycin or in paraquat poisoning due to the demonstration of:
• Potentiation of lung injury by oxygen 22, 23 • Lack of harm from hypoxaemia with saturations around 85% in these clinical situations 24 
11
The potential advantages of nasal cannulae as an initial method of delivering oxygen therapy are:
• Ability to give nebulized bronchodilator at the same time as oxygen is administered.
• Oxygen can be prescribed by variable flows to achieve a target saturation range rather than a fixed FiO2, although oxygenation may be maintained better with a Venturi mask.
32
• Comfort, ease of use and low cost.
• Less likely to be taken off to eat or speak, and less likely to fall off.
• No risk of rebreathing of carbon dioxide. 12 Humidified high flow nasal cannulae are an alternative to standard low flow nasal cannulae or high flow masks for oxygen delivery. 34, 40, 41, [91] [92] [93] There are no published evidence-based guidelines for their clinical use in adults; however, currently, some centres recommend high flow nasal cannulae only in the emergency department, HDU or ICU. The potential advantages, demonstrated mostly from observational studies, of this delivery system include:
• Greater comfort and tolerance via delivery of warmed and humidified nasal oxygen, compared with delivery via a face mask.
• Better titration of FiO2 across a wider range of FiO2.
• Preservation of upper airways function, such as speech, swallowing and cough. Potential disadvantages of high flow nasal cannualae include:
• Risk of complacency if a high FiO2 requirement is not recognized to represent life-threatening illness requiring more than correction of hypoxaemia.
• Role in severe exacerbations of COPD and asthma has not been investigated.
